Trials / Unknown
UnknownNCT02663440
Trial of Hypofractionated Intensity Modulated Radiation Therapy With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor for Patients With Newly Diagnosed Glioblastoma Multiforme
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- Sponsor
- Zhejiang Cancer Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Phase II Trial of Hypofractionated Intensity Modulated Radiation Therapy(IMRT) With Temozolomide and Granulocyte-macrophage Colony-stimulating Factor(GM-CSF) for Patients With Newly Diagnosed Glioblastoma Multiforme.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| RADIATION | Hypofractionated IMRT | Hypofractionated IMRT |
| BIOLOGICAL | Granulocyte-macrophage Colony-stimulating Factor | Granulocyte-macrophage Colony-stimulating Factor |
| DRUG | Temozolomide | Temozolomide |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2017-12-01
- First posted
- 2016-01-26
- Last updated
- 2016-01-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02663440. Inclusion in this directory is not an endorsement.